Sales & Marketing News | pharmaphorum

News

Allergan, Teva considering $5bn play to shake off opioid han...

AbbVie's Allergan subsidiary and Teva are reportedly considering making a $5 billion-plus offer to try to bring opioid liability lawsuits to a conclusion.

News

Pfizer upgrades Biohaven alliance to a takeover bid

Not content with a $1.2 billion licensing deal for Biohaven Pharma's oral migrain

News

Ex-Sanofi CEO backs first European biomanufacturing SPAC

A new "black cheque" company that claims to be the first in Europe devoted to biomanufacturing has been set up by a team of investors, including former Sanofi chief executive Gerard le Fur.

News

Seagen CEO on leave amid domestic abuse allegations

Seagen's chief executive Clay Siegall has taken leave of absence pending an investigation into an alleged domestic violence incident at his home.

News

Manufacturing foul-up hits Novartis' radioligand business

Novartis has shut down production of its radioligand therapies – one of its key

News

Idorsia is first to EU market with orexin insomnia drug

Idorsia has become the first drugmaker in the EU to claim approval for a drug for chronic insomnia in the dual orexin receptor antagonist class, ahead of rival drugs from Merck & Co and

Allergan, Teva considering $5bn play to shake off opioid han...

Pfizer upgrades Biohaven alliance to a takeover bid

Ex-Sanofi CEO backs first European biomanufacturing SPAC

Seagen CEO on leave amid domestic abuse allegations

Manufacturing foul-up hits Novartis' radioligand business

Idorsia is first to EU market with orexin insomnia drug

On the benefits of earlier oncological intervention, with Jo...

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks